Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Share-based Compensation (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Share-based Compensation data on record, last reported at $598000.0 in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 3.55% year-over-year to $598000.0; the TTM value through Sep 2025 reached $2.2 million, down 44.05%, while the annual FY2024 figure was $3.3 million, 5.66% down from the prior year.
  • Share-based Compensation reached $598000.0 in Q3 2025 per PLX's latest filing, up from $427000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.4 million in Q4 2023 and bottomed at $288000.0 in Q2 2022.
  • Average Share-based Compensation over 5 years is $669789.5, with a median of $578000.0 recorded in 2021.
  • Peak YoY movement for Share-based Compensation: plummeted 60.18% in 2021, then skyrocketed 159.95% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $418000.0 in 2021, then rose by 28.95% to $539000.0 in 2022, then soared by 153.62% to $1.4 million in 2023, then plummeted by 52.16% to $654000.0 in 2024, then fell by 8.56% to $598000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $598000.0 in Q3 2025, $427000.0 in Q2 2025, and $540000.0 in Q1 2025.